Innovation Incentives: Comparing Options

The Multiple Choice Problem: When Three Instruments Compete for the Same Euro

Between 2024 and 2026, we observed a consistent pattern among innovative Portuguese companies: organisations with eligible expenses above €300,000 per year are leaving between €85,000 and €420,000 in tax and non-repayable benefits on the table. Not due to lack of awareness—most know SIFIDE II, RFAI and the innovation components of PT2030—but due to the inability to model accumulation scenarios without creating eligibility conflicts or exposure to subsequent corrections.

The Portuguese context in 2026-2027 presents three main innovation incentive instruments that partially overlap:

• SIFIDE II (Sistema de Incentivos Fiscais em I&D Empresarial): deduction from CIT up to 82, significant gains from eligible expenses, applicable to CIT
• RFAI (Regime Fiscal de Apoio ao Investimento): deduction up to significant gains from eligible investment (including assets for R&D), applicable to CIT and limited by company size
• PT2030 Innovation Component: non-repayable incentives between significant gains depending on project type and location, not applicable to costs already deducted for tax purposes

The complexity arises at the intersection: a prototyping equipment may be eligible for all three instruments, but the allocation strategy determines whether you recover significant gains or significant gains from the investment. Moreover, a wrong choice in 2026 can compromise eligibility for 2027 applications or create deferred tax liabilities of €180,000+ that only emerge in tax audits three years later.

Our experience in incentives and financing shows that companies applying structured decision protocols capture, on average, significantly more net benefit than those treating each instrument in isolation. This article details that protocol.

Why This Matters Now: The 2026-2027 Cycle and the Fiscal Planning Window

Three factors make comparative analysis of innovation incentives in Portugal especially critical for decisions taken between Q1 2026 and Q2 2027:

1. Phased Opening of PT2030 Calls with Finite Budgets

Portugal 2030 operates on a call-for-proposals basis: calls open with a defined budget and close when funds are exhausted or at the deadline. Data from the Agency for Competitiveness and Innovation (IAPMEI) indicate that in 2025, significant gains from business innovation calls exhausted their budgets before the deadline, with an average opening period of 47 days. Companies that did not plan ahead were excluded from non-repayable incentives of €250,000–2M.

For 2026-2027, the main expected calls include:

• Productive Innovation (estimated budget €450M, base rate significant gains)
• Qualification and Internationalisation (€180M, rate significant gains)
• Digital Transition and Innovation (€320M, rate significant gains)

The decision to apply cannot be made in isolation: it must be integrated with the SIFIDE II tax strategy (submission deadline is 30 June of the following year) and RFAI (applicable in the year of investment). As detailed in our comprehensive PT2030 guide, the sequence of decisions matters as much as the decisions themselves.

2. SIFIDE II Regulatory Changes Effective January 2026

Decree-Law No. 72/2025 introduced three structural changes to SIFIDE II:

• New definition of eligible expenses: excluded external certification costs for projects below €500,000, but included digital prototyping costs (simulation software) up to significant gains of the total
• Explicit accumulation limit: expenses benefiting from a non-repayable incentive ≥ significant gains cannot be included in the SIFIDE base (previously, the limit was implicit and led to divergent interpretations)
• Bonus for collaborative projects: incremental rate of significant gains for consortium projects with higher education institutions, applicable to expenses with PhD researchers

These changes radically alter the accumulation mathematics. In a €800,000 project with significant PT2030 incentive, the eligible SIFIDE base can be zero or €480,000 depending on how the application is structured and costs are allocated between categories.

3. Cash Flow Pressure and the Need to Accelerate Free Cash Flow

With Euribor rates stabilised at 2.8–3, significant gains (ECB data, February 2026) and innovation credit lines with an average spread of 2, significant gains, the cost of capital for innovative SMEs is between 5.2–5, significant gains. This makes the timing of incentive receipts critical for the project's NPV.

Comparison of typical cash flow profiles (project of €1M):

The NPV difference between an optimised strategy (prioritising PT2030 for fast-execution costs and reserving SIFIDE for current expenses) and a naive strategy can reach €140,000 in mid-scale projects. For further insight on the relationship between incentives and cash management, see our article on financial process automation, where we document how CFOs integrate these decisions into approval workflows.

Decision Framework: The Optimal Incentive Allocation Matrix (MAOI)

Over 47 applications between 2023–2025, we developed a four-phase protocol to maximise capture of innovation incentives without creating eligibility conflicts. Internally, we call this the MACRO® Incentive Allocation Method, structured as a sequential decision matrix.

Phase 1: Classification of Expenses by Cross-Eligibility

The most common mistake is to treat "R&D expenses" as a homogeneous category. In practice, each budget line has a different eligibility profile across the three instruments:

Type A: Eligible under all three instruments (maximum conflict zone)

• Scientific and laboratory equipment
• Development and simulation software
• Expenses with PhD researchers working exclusively

Type B: Eligible for SIFIDE + PT2030 (not RFAI)

• Prototyping and testing costs
• Raw materials for product development
• Participation in international collaborative projects

Type C: Eligible only for SIFIDE

• Current expenses with non-PhD researchers
• Laboratory consumables
• Participation in conferences and specialised training

Type D: Eligible only for PT2030

• Facility adaptation works (within limits)
• Specialised consultancy for certifications
• Innovation marketing and dissemination actions

The MAOI matrix starts by classifying each project budget line into these four types. In a typical €1.2M project we supported in 2025 (medical devices sector), the distribution was:

• Type A: €420,000 (significant gains)
• Type B: €380,000 (significant gains)
• Type C: €280,000 (significant gains)
• Type D: €120,000 (significant gains)

This initial classification already shows that only significant gains of the budget are in a critical decision zone. The remaining significant gains have deterministic allocation.

Phase 2: Calculation of Effective Rates per Allocation Scenario

For Type A expenses (conflict zone), we build a table of effective rates considering:

• Nominal rate: incentive percentage before tax and limitations
• Effective post-CIT rate: considering that non-repayable incentives are taxable income
• Net cash rate: adjusted for timing of receipt and cost of capital

Scenario 1: Priority Allocation to PT2030

Expense: €100,000 in Type A equipment

PT2030 incentive (significant gains): €50,000

CIT impact (significant gains on incentive): -€10,500

Immediate net benefit: €39,500

Residual SIFIDE-eligible expense: €0 (due to ≥ significant gains rule)

Total benefit: €39,500 (effective rate 39, significant gains)

Scenario 2: Priority Allocation to SIFIDE II

Expense: €100,000 in Type A equipment

SIFIDE base (significant gains): €100,000

Incremental rate (expense above previous base): significant gains

Deduction from CIT: €50,000

Limitation (significant gains of CIT): assuming sufficient CIT

SIFIDE benefit: €50,000

Not eligible for PT2030 (already deducted for tax purposes)

Total benefit: €50,000 (effective rate significant gains)

Scenario 3: Strategic Mixed Allocation

Expense: €100,000 split into two separate contractual components

Component 1 (€30,000): base equipment → PT2030

Incentive: €15,000 (significant gains)

CIT impact: -€3,150

Net: €11,850

Component 2 (€70,000): technical upgrade → SIFIDE

Deduction: €35,000 (significant gains)

Total benefit: €46,850 (effective rate 46, significant gains)

The complete table for this specific project (medical devices) showed that Scenario 2 (SIFIDE priority) was optimal for this company because:

• Projected CIT of €340,000 allowed full deduction absorption
• Type B+C expenses (€660,000) already ensured sufficient PT2030 base to meet the minimum application threshold (€500,000)
• 18-month execution period made timing difference irrelevant (both instruments paid in 2027)

But in significant gains of the cases we analysed, the optimal scenario is mixed, requiring careful contractual structuring. Financial modelling of these alternatives benefits from discounted free cash flow analysis tools.

Phase 3: Testing Regulatory Restrictions and Limits

Each instrument has absolute and relative limits that may render the theoretically optimal scenario unfeasible:

SIFIDE II Limits

• Maximum deduction: €1,500,000 per company per fiscal year
• Deduction limited to significant gains of CIT for the year (with 8-year carry-forward for surplus)
• Maximum eligible expenses: no absolute cap, but marginal deduction decreases (base rate 32, significant gains up to reference expense, then significant gains incremental up to 1.5x, then 82, significant gains above)

RFAI Limits

• SME: deduction up to significant gains of eligible investment, maximum €5,000,000 per tax period
• Non-SME: significant gains of investment, maximum €2,000,000
• Limited to significant gains of CIT (no carry-forward)
• Incompatible with other tax benefits on the same asset (except SIFIDE under specific conditions)

PT2030 Limits

• Maximum aid intensity: varies by region (significant gains Mainland, significant gains Madeira, significant gains Azores) and size (bonus + significant gains SME, + significant gains micro)
• Minimum amount: €500,000 eligible investment (most calls)
• Maximum amount: €5,000,000 incentive (standard calls), €15,000,000 (structuring projects)
• De minimis aid rule: €300,000 per company with a realistic fiscal period (if applicable)

Phase 3 of MAOI applies these limits to the scenario selected in Phase 2. Real example (software company, 2025):

Initial scenario (Phase 2):

PT2030 allocation: €800,000 (rate significant gains) → incentive €400,000

SIFIDE allocation: €1,100,000 → deduction €687,500

Theoretical total benefit: €1,087,500

After applying limits (Phase 3):

Projected CIT: €420,000

SIFIDE limit (significant gains of CIT): €294,000

Surplus for carry-forward: €393,500

NPV of surplus (5, significant gains discount, average 4 years): €312,000

Adjusted total benefit: €1,006,000

This company had insufficient CIT to absorb SIFIDE in the year. Solution: rebalance to increase PT2030 (no CIT limit) and reduce SIFIDE to the absorbable limit, increasing net benefit by €34,000.

Phase 4: Temporal Optimisation and Multi-Year Strategy

R&D projects rarely fit within a single fiscal year. MAOI integrates a multi-year perspective:

Expense Phasing Strategy

If the project runs from 2026–2028, you can distribute Type A expenses across years to:

• Maximise annual SIFIDE absorption (avoid excessive carry-forward)
• Take advantage of multiple PT2030 calls (if eligible for different types)
• Manage three-year de minimis limits

Sequential Application Strategy

A €4M structuring project can be segmented into:

• Phase 1 (2026): Pilot project €800,000 → PT2030 Productive Innovation
• Phase 2 (2027): Industrial scale-up €2,200,000 → PT2030 Digital Transition
• Phase 3 (2028): Internationalisation €1,000,000 → PT2030 Qualification
• Transversal: SIFIDE II applied annually to current expenses not covered

This approach, detailed in the article on preparing PT2030 applications, enables capture of €2,100,000 in non-repayable incentives + €890,000 SIFIDE, versus €1,400,000 + €720,000 in a monolithic approach.

The complete MAOI matrix produces three outputs:

• Optimal allocation plan: detailed line-by-line table with assigned instrument
• Application timeline: submission dates, execution deadlines, reporting milestones
• Cash flow projection: monthly incentive inflows, integrated with the investment plan

In the MACRO® Method, this matrix is reviewed quarterly during project execution, as regulatory changes (new calls, rate changes) or execution deviations may justify rebalancing.

Technical Comparative Analysis: SIFIDE II vs RFAI vs PT2030 Innovation

This section details the three instruments in technical depth, focusing on eligibility criteria, calculation mechanics and integration/conflict points.

SIFIDE II: Corporate R&D Tax Incentive System

Calculation Mechanics (updated 2026)

SIFIDE II operates as a CIT deduction, with a variable rate depending on incremental expense:

Base rate: 32, significant gains of eligible expenses up to the amount of expenses from the previous period (or the average of the previous two periods, whichever is more favourable)

Incremental rate level 1: significant gains of expenses between significant gains and significant gains of the reference base

Incremental rate level 2: 82, significant gains of expenses above significant gains of the reference base

Bonus for collaborative projects: +15 p.p. on expenses with PhD researchers in projects with higher education institutions (new in 2026)

Calculation example (company with history):

R&D expenses 2025: €400,000

R&D expenses 2026: €650,000

Reference base: €400,000

Increment: €250,000

2026 deduction calculation:

Base tier (€400,000): €400,000 × 32, significant gains = €130,000

Incremental tier 1 (€200,000): €200,000 × significant gains = €100,000

Incremental tier 2 (€50,000): €50,000 × 82, significant gains = €41,250

Total deduction: €271,250

If €80,000 of expenses are for PhDs in a collaborative project:

Bonus: €80,000 × significant gains = €12,000

Total enhanced deduction: €283,250

Eligible Expenses (Full Taxonomy)

• Category 1 — Personnel: salaries of researchers, technicians and assistants assigned to R&D, including social charges. Requires timesheet records if partial allocation. No absolute cap, but must be proportional to actual time spent
• Category 2 — Equipment: depreciation of equipment used exclusively for R&D. For mixed use, only demonstrable share. Includes development software (new in 2026: simulation and digital prototyping up to significant gains of total)
• Category 3 — Subcontracting: expenses with external entities for R&D execution, up to significant gains of total eligible expenses. If subcontractor is a related entity, limit reduced to significant gains
• Category 4 — Others: consumables, raw materials for prototypes, patent registration costs (up to €30,000/year), participation in scientific conferences (up to €15,000/year)

Proof Obligations

Mandatory technical dossier containing:

• Detailed description of the R&D project (objectives, methodology, innovative character)
• Identification of researchers and their qualifications
• Expense map by category with supporting documents
• External certification (mandatory if expenses > €500,000)

Submission deadline: until 30 June of the year following the expenses (e.g. 2026 expenses submitted by 30/06/2027).

Critical Points of Attention

The Tax Authority has intensified SIFIDE audits since 2024. Main reasons for correction:

• Over-qualification of activities: product development without fundamental or applied research component. Rule of thumb: if the result was predictable with existing knowledge, it is not R&D
• Double counting with PT2030: including in the SIFIDE base expenses that received a non-repayable incentive ≥ significant gains
• Lack of accounting segregation: not having separate analytical accounts for R&D projects

RFAI: Fiscal Support Regime for Investment

Calculation Mechanics

Deduction from CIT of significant gains (SME) or significant gains (large company) of eligible investment made, limited to significant gains of CIT for the year. No carry-forward: what is not deducted in the year is lost.

Eligible investment includes:

• Tangible fixed assets (except land, non-industrial buildings, passenger cars)
• Intangible assets (software, patents, licences) if related to productive activity

Example (industrial SME):

2026 investment:

Production equipment: €400,000

ERP software: €80,000

Commercial vehicle: €35,000 (not eligible)

Eligible base: €480,000

RFAI deduction: €480,000 × significant gains = €120,000

CIT 2026: €180,000

Limit (significant gains of CIT): €90,000

Effective deduction: €90,000

Surplus €30,000: lost (no carry-forward)

Access Conditions

• Company with organised accounting
• Regularised tax and social security status
• Investment retained in the company for at least 5 years (3 years if SME)
• Not having benefited from de minimis aid exceeding limits (if applicable)

Compatibility